Evidence map›Paper›PMID 28158734›Full record

ArticleThe international journal of neuropsychopharmacology2017

Activation of Extracellular Signal-Regulated Kinases (ERK 1/2) in the Locus Coeruleus Contributes to Pain-Related Anxiety in Arthritic Male Rats.

Gisela Borges, Cristina Miguelez, Fani Neto, Juan Antonio Mico, Luisa Ugedo, Esther Berrocoso

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Gisela BorgesNeuropsychopharmacology and Psychobiology Research Group, Department of Neuroscience, University of Cádiz, Cádiz, Spain (Drs Borges and Mico); Departamento de Biomedicina-Unidade de Biologia Experimental, da Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal (Drs Borges and Neto); Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal (Drs Borges and Neto); Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Spain (Drs Miguelez and Ugedo); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (Drs Mico and Berrocoso); Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain (Dr Berrocoso); Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain (Drs Mico and Berrocoso).
Cristina MiguelezNeuropsychopharmacology and Psychobiology Research Group, Department of Neuroscience, University of Cádiz, Cádiz, Spain (Drs Borges and Mico); Departamento de Biomedicina-Unidade de Biologia Experimental, da Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal (Drs Borges and Neto); Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal (Drs Borges and Neto); Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Spain (Drs Miguelez and Ugedo); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (Drs Mico and Berrocoso); Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain (Dr Berrocoso); Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain (Drs Mico and Berrocoso).
Fani NetoNeuropsychopharmacology and Psychobiology Research Group, Department of Neuroscience, University of Cádiz, Cádiz, Spain (Drs Borges and Mico); Departamento de Biomedicina-Unidade de Biologia Experimental, da Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal (Drs Borges and Neto); Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal (Drs Borges and Neto); Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Spain (Drs Miguelez and Ugedo); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (Drs Mico and Berrocoso); Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain (Dr Berrocoso); Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain (Drs Mico and Berrocoso).
Juan Antonio MicoNeuropsychopharmacology and Psychobiology Research Group, Department of Neuroscience, University of Cádiz, Cádiz, Spain (Drs Borges and Mico); Departamento de Biomedicina-Unidade de Biologia Experimental, da Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal (Drs Borges and Neto); Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal (Drs Borges and Neto); Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Spain (Drs Miguelez and Ugedo); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (Drs Mico and Berrocoso); Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain (Dr Berrocoso); Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain (Drs Mico and Berrocoso).
Luisa UgedoNeuropsychopharmacology and Psychobiology Research Group, Department of Neuroscience, University of Cádiz, Cádiz, Spain (Drs Borges and Mico); Departamento de Biomedicina-Unidade de Biologia Experimental, da Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal (Drs Borges and Neto); Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal (Drs Borges and Neto); Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Spain (Drs Miguelez and Ugedo); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (Drs Mico and Berrocoso); Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain (Dr Berrocoso); Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain (Drs Mico and Berrocoso).
Esther BerrocosoNeuropsychopharmacology and Psychobiology Research Group, Department of Neuroscience, University of Cádiz, Cádiz, Spain (Drs Borges and Mico); Departamento de Biomedicina-Unidade de Biologia Experimental, da Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal (Drs Borges and Neto); Instituto de Biologia Molecular e Celular (IBMC) e Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal (Drs Borges and Neto); Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Spain (Drs Miguelez and Ugedo); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain (Drs Mico and Berrocoso); Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain (Dr Berrocoso); Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain (Drs Mico and Berrocoso).
Centro de Investigación Biomédica en Red de Salud Mental · ESBiomedical Research and Innovation Institute of Cadiz · ESHospital Universitario Puerta del Mar · ESi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is increasing evidence suggesting that the Locus Coeruleus plays a role in pain-related anxiety. Indeed, we previously found that prolonged arthritis produces anxiety-like behavior in rats, along with enhanced expression of phosphorylated extracellular signal-regulated kinase 1/2 (a marker of plasticity) in the Locus Coeruleus. However, it is unknown how this effect correlates with the electrophysiological activity of Locus Coeruleus neurons or pain-related anxiety. Methods: Using the complete Freund's adjuvant model of monoarthritis in male Sprague-Dawley rats, we studied the behavioral attributes of pain and anxiety as well as Locus Coeruleus electrophysiology in vivo 1 (MA1W) and 4 weeks (MA4W) after disease induction. Results: The manifestation of anxiety in MA4W was accompanied by dampened tonic Locus Coeruleus activity, which was coupled to an exacerbated evoked Locus Coeruleus response to noxious stimulation of the inflamed and healthy paw. When a mitogen-activating extracellular kinase inhibitor was administered to the contralateral Locus Coeruleus of MA4W, the phosphorylated extracellular signal-regulated kinase 1/2 levels in the Locus Coeruleus were restored and the exaggerated evoked response was blocked, reversing the anxiogenic-like behavior while pain hypersensitivity remained unaltered. Conclusion: As phosphorylated extracellular signal-regulated kinase 1/2 blockade in the Locus Coeruleus relieved anxiety and counteracted altered LC function, we propose that phosphorylated extracellular signal-regulated kinase 1/2 activation in the Locus Coeruleus plays a crucial role in pain-related anxiety.

Indexed as

Action PotentialsAminoacetonitrileAnimalsAnxietyArthritis, ExperimentalCohort StudiesExtracellular Signal-Regulated MAP KinasesFreund's AdjuvantLocus CoeruleusMaleNeuronsNociceptionPainPhosphorylationProtease InhibitorsRats, Sprague-DawleyAminoacetonitrileExtracellular Signal-Regulated MAP KinasesFreund's AdjuvantProtease InhibitorsSL 327Tyrosine 3-MonooxygenaseanxietyarthritisERK1/2Locus Coeruleuspain

Identifiers

PMID28158734
PMCPMC5458337
OpenAlexW2624285448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.